Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
Why the study?
Does the addition of bevacizumab to chemotherapy increase the risk of venous thromboembolic events in patients with cancer?
Population
6,055 patients with cancer from 10 randomized phase II and III studies
Comparison
Bevacizumab added to chemotherapy vs Chemotherapy alone (controls)
Design
Meta-analysis, Included studies were randomized
Authors
Discussion
Loading...
Member takes
Implication
Bevacizumab addition to chemotherapy does not increase VTE risk; confirms safety and supports continued use in cancer patients.
Structured PICO
Does the addition of bevacizumab to chemotherapy increase the risk of venous thromboembolic events in patients with cancer?
P
Population
6,055 patients with cancer from 10 randomized phase II and III studies
I
Intervention
Bevacizumab added to chemotherapy
C
Comparator
Chemotherapy alone (controls)
O
Outcome
Incidence of venous thromboembolisms (VTEs) (unadjusted and exposure-adjusted)safety
The addition of bevacizumab to chemotherapy does not significantly increase the risk of venous thromboembolic events compared to chemotherapy alone in patients with cancer.
Cite This Study
Hurwitz et al. (2011) studied this question.